无形易布鲁替尼的热稳定性的表征
Dan Trunov1, Jan Ižovský1, Josef Beranek2
1Department of Chemical Engineering, University of Chemistry and Technology, Technická 3, Prague 6, Dejvice 166 28, Czech Republic.
概括
选择正确的药物无形化方法是活性药物成分的关键. 这项研究比较了无形易布鲁替尼的技术,揭示了温度.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
- 化学工程是化学工程的重要组成部分.
背景情况:
- 药物无形化对于提高溶解性和生物可用性至关重要.
- 选择适当的无形化技术需要考虑药物的特性和可扩展性.
- 无形固体分散通常需要辅助剂来提高稳定性和性能.
研究的目的:
- 为了比较各种无形化技术来制备无形的易布鲁替尼.
- 研究无形化方法对ibrutinib的物理化学性质,稳定性和降解的影响.
- 探索温度在控制易布鲁替尼的可溶性,透性和降解产品形成中的作用.
主要方法:
- 融火灭器的使用方法
- 热挤出方式 热挤出
- 溶剂的蒸发是溶剂的蒸发.
- 球磨机 球磨机 球磨机
- 软化液化化是什么意思
- 物理化学表征 物理化学表征
- 稳定性研究 稳定性研究
- 齐姆的情节分析分析.
主要成果:
- 温度显著影响易布鲁替尼的溶解性和透性,通过降解产品进行介导.
- 降解产品具有聚合的潜力,增加分子量.
- 形态化温度控制了杂质的数量,聚合率和结构.
- 采用齐姆图分析来确定降解产品的分子量,这是这一类分子的新应用.
结论:
- 无形化方法和过程参数的选择,特别是温度,极大地影响无形易布鲁替尼的质量和稳定性.
- 了解和控制降解途径对于开发稳定的无形药物配方至关重要.
- 这项研究为无形制药中的杂质的表征和控制提供了新的见解.
相关概念视频
Polymer Classification: Crystallinity
2.8K
Unlike ionic or small covalent molecules, polymers do not form crystalline solids due to the diffusion limitations of their long-chain structures. However, polymers contain microscopic crystalline domains separated by amorphous domains.
Crystalline domains are the regions where polymer chains are aligned in an orderly manner and held together in proximity by intermolecular forces. For example, chains in the crystalline domains of polyethylene and nylon are bound together by van der Waals...
Crystalline domains are the regions where polymer chains are aligned in an orderly manner and held together in proximity by intermolecular forces. For example, chains in the crystalline domains of polyethylene and nylon are bound together by van der Waals...
2.8K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
281
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
281


